Pragma Bio
About Pragma Bio
Pragma Bio utilizes microbiome analysis to identify and develop therapeutic compounds for the treatment of cancer and autoimmune diseases. By targeting specific microbial interactions, the company aims to create effective, personalized treatments that address the underlying biological mechanisms of these conditions.
```xml <problem> Traditional drug discovery methods often rely on target-first approaches and synthetic molecule libraries, leading to high clinical trial failure rates due to a lack of efficacy. Current methods may not fully leverage the potential of naturally evolved molecules and the complex interactions within the gut-immune axis. </problem> <solution> Pragma Bio employs a biology-first, AI-enabled platform called PIKASO to discover novel small molecule therapeutics derived from the gut microbiome. The platform mines clinically-relevant Biosynthetic Gene Clusters (BGCs) using real-world evidence and multi-omics datasets to identify molecules that modulate the gut-immune axis. Pragma Bio leverages synthetic biology and chemistry tools to synthesize, analyze, and derivatize these BGCs and their small molecule products. The company then tests these molecules in models of disease biology to select candidates for further optimization and characterization, ultimately deciphering their molecular target and mechanism of action. </solution> <features> - AI-driven bioinformatics platform for mining clinically-relevant BGCs from multi-omics datasets - End-to-end data-to-molecule discovery pipeline powered by a BGC database - Expertise in synthesizing novel small molecules for New Chemical Entity (NCE) optimization - Phenotypic screening to uncover new disease-modifying pathways and targets - Pharmacology testing in disease models to select and characterize drug candidates - Focus on mining naturally evolved molecules enriched with immune system modulators </features> <target_audience> Pragma Bio's primary target audience includes pharmaceutical companies and research organizations focused on developing novel therapeutics for cancer and autoimmune diseases by targeting the gut-immune axis. </target_audience> ```
What does Pragma Bio do?
Pragma Bio utilizes microbiome analysis to identify and develop therapeutic compounds for the treatment of cancer and autoimmune diseases. By targeting specific microbial interactions, the company aims to create effective, personalized treatments that address the underlying biological mechanisms of these conditions.
Where is Pragma Bio located?
Pragma Bio is based in Millbrae, United States.
When was Pragma Bio founded?
Pragma Bio was founded in 2018.
How much funding has Pragma Bio raised?
Pragma Bio has raised 14515000.
- Location
- Millbrae, United States
- Founded
- 2018
- Funding
- 14515000
- Employees
- 26 employees
- Major Investors
- Plug and Play, Viking Global Investors, Hike Ventures, Social Starts, The Venture Collective